`Patent 8,114,833 B2
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________
`
`MYLAN INSTITUTIONAL LLC and PFIZER INC.,
`Petitioners,
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner.
`______________
`
`Case IPR2020-003241
`Patent 8,114,833
`______________
`
`PATENT OWNER’S NOTICE OF DEPOSITION
`OF DR. LAIRD FORREST
`
`
`
`
`
`
`
`
`1 IPR2020-01252 has been joined with this proceeding.
`
`
`
`
`
`
`
`IPR2020-00324
`Patent 8,114,833 B2
`
`Pursuant to 37 C.F.R. § 42.53, Patent Owner Novo Nordisk A/S (“Patent
`
`Owner”) hereby provides notice that it will conduct cross-examination by
`
`deposition of Dr. Laird Forrest, a witness of Petitioners, Mylan Institutional LLC
`
`and Pfizer Inc. The deposition will be conducted by videoconference or other
`
`remote means, and will begin on January 13, 2021 at 9:00 a.m. (unless otherwise
`
`agreed), continuing day to day thereafter until completed.
`
`The cross-examination will be taken before a Notary Public or other officer
`
`authorized by law to administer oaths. The cross-examination will be recorded by
`
`stenographic and/or audio means. It may also be transcribed by real-time reporting
`
`software and recorded by a videographer.
`
`
`
`Dated: December 23, 2020
`
`
`
`Respectfully submitted,
`
`
`
`
`/Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`FENWICK & WEST LLP
`902 Broadway, Suite 14
`New York, NY 10010
`(212) 430-2600 (tel)
`(650) 938-5200 (fax)
`joelke@fenwick.com
`
`Counsel for Novo Nordisk A/S
`
`
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that a copy of the foregoing Patent Owner’s
`
`Notice of Deposition was served on December 23, 2020, by filing this document
`
`through the Patent Trial and Appeal Board End to End System, as well as delivering
`
`a copy via electronic mail upon the following attorneys of record for the Petitioners:
`
`Brandon M. White (Reg. No. 52,354)
`Perkins Coie LLP
`700 Thirteenth Street, N.W., Suite 600
`Washington, D.C. 20005
`Telephone: (202) 654-6206
`White-ptab@perkinscoie.com
`
`Lara Dueppen (Reg. No. 65,002)
`Perkins Coie LLP
`1888 Century Park East
`Suite 1700
`Los Angeles, CA 90067
`Telephone: (310) 788-3349
`Dueppen-ptab@perkinscoie.com
`Liraglutide@perkinscoie.com
`
`Emily J. Greb (Reg. No. 68,244)
`Perkins Coie LLP
`33 East Main Street, Suite 201
`Madison, WI 53703
`Telephone: (608) 663-7494
`Fax: (608) 283-4494
`Greb-ptab@perkinscoie.com
`
`
`
`
`
`
`
`
`
`
`
`
`35126/00413/FW/11752000.1
`
`
`
`Respectfully submitted,
`
`
`
`/ Jeffrey J. Oelke/
`Jeffrey J. Oelke (Reg. No. 37,409)
`
`Counsel for Novo Nordisk A/S
`
`IPR2020-00324
`Patent 8,114,833 B2
`
`Jovial Wong (Reg. No. 60,115)
`Sharon Lin
`Winston & Strawn LLP
`1901 L St. NW
`Washington, DC 20036
`Telephone: (202) 282-5000
`Fax: (202) 282-5100
`jwong@winston.com
`slin@winston.com
`
`
`
`
`Date: December 23, 2020
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`